MedTrace Logo

Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne

NCT05704114 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-01-30

No results posted yet for this study

Summary

The purpose of the study is to assess the safety and efficacy of Arazlo Lotion (Tazarotene 0.045% Lotion) for treatment of postinflammatory erythema and postinflammatory hyperpigmentation in subjects with acne.

Conditions

  • Acne Vulgaris
  • Post Inflammatory Hyperpigmentation
  • Post Inflammatory Pigmentation Change
  • Erythema
  • Skin Scarring

Interventions

DRUG

Tazarotene 0.045% Lotion

Daily topical use of tazarotene for 16 weeks.

Sponsors & Collaborators

  • Dr. Emmy Graber

    lead OTHER

Principal Investigators

  • Emmy Graber · The Dermatology Insitutue of Boston

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-02-01
Completion
2022-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05704114 on ClinicalTrials.gov